Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 220

1.

AIDS and HIV Infection after Thirty Years.

Ippolito G, Levy JA, Sonnerborg A, Mugusi F, Dianzani F.

AIDS Res Treat. 2013;2013:731983. doi: 10.1155/2013/731983. No abstract available.

2.

Nonspecific Defenses.

Dianzani F, Baron S.

In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 49.

3.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts..

BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23.

4.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC)., Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

5.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Antiretroviral Therapy Cohort Collaboration (ART-CC)., Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA.

AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130.

6.

Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Riva E, Maggi F, Abbruzzese F, Bellomi F, Giannelli G, Picardi A, Scagnolari C, Folgori A, Spada E, Piccolella E, Dianzani F, Antonelli G; Acute Hepatitis C Italian Study Group..

Med Microbiol Immunol. 2009 Feb;198(1):13-8. doi: 10.1007/s00430-008-0099-9.

PMID:
18696111
7.

Interferon may prevent HIV viral rebound after HAART interruption in HIV patients.

Dianzani F, Rozera G, Abbate I, D'Offizi G, Abdeddaim A, Vlassi C, Antonucci G, Narciso P, Martini F, Capobianchi MR.

J Interferon Cytokine Res. 2008 Jan;28(1):1-3. doi: 10.1089/jir.2007.0076.

PMID:
18370866
8.

Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis.

Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moioli C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group..

Infection. 2008 Feb;36(1):46-53. doi: 10.1007/s15010-007-6300-z.

PMID:
18231722
9.

Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.

D'Offizi G, Martini F, Rozera G, Abbate I, Capobianchi MR, Narciso P, Dianzani F.

AIDS. 2008 Jan 11;22(2):321. No abstract available.

PMID:
18097242
10.

What is the practical significance of antibodies to interferons?

Dianzani F, Antonelli G.

BioDrugs. 1998 Mar;9(3):187-95.

PMID:
18020559
11.

Markers of human papillomavirus infection and their correlation with cervical dysplasia in human immunodeficiency virus-positive women.

Riva E, Serraino D, Pierangeli A, Bambacioni F, Zaniratti S, Minosse C, Selleri M, Bucci M, Scagnolari C, Degener AM, Capobianchi MR, Antonelli G, Dianzani F; Roman Papillomavirus Study Group*..

Clin Microbiol Infect. 2007 Jan;13(1):94-7.

12.

Influence of GBV-C infection on the endogenous activation of the IFN system in HIV-1 co-infected patients.

Capobianchi MR, Lalle E, Martini F, Poccia F, D'Offizi G, Antonucci G, Abbate I, Dianzani F.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):3-8.

PMID:
16914092
13.

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V.

J Antimicrob Chemother. 2006 Jun;57(6):1055-64.

PMID:
16606637
14.

Considerations on the development of serum antibodies to interferon-beta.

Antonelli G, Bagnato F, Dianzani F.

New Microbiol. 2005 Jul;28(3):183-92. Review.

PMID:
16240689
15.

Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.

Abbate I, Cappiello G, Longo R, Ursitti A, Spanò A, Calcaterra S, Dianzani F, Antinori A, Capobianchi MR.

Infect Genet Evol. 2005 Apr;5(3):247-53.

PMID:
15737916
16.

Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.

Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G.

Antivir Ther. 2004 Dec;9(6):1003-11.

PMID:
15651759
17.

Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.

Dianzani F, Frascione E.

Scand J Infect Dis Suppl. 2003;106:108-9. No abstract available.

PMID:
15000599
18.

Viral resistance to chemotherapeutic agents: an expectable unexpected phenomenon.

Dianzani F.

Scand J Infect Dis Suppl. 2003;106:6-7. Review. No abstract available.

PMID:
15000573
19.

Human immunodeficiency virus (HIV) DNA load and level of immunosuppression in treatment-naive HIV-1-infected patients.

Riva E, Antonelli G, Scagnolari C, Pistello M, Capobianchi MR, Monforte Ad, Pezzotti P, Dianzani F; I.CO.N.A. Study Group..

J Infect Dis. 2003 Jun 1;187(11):1826-8. No abstract available.

PMID:
12751043
20.

Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Scagnolari C, Casato M, Bellomi F, De Pisa F, Turriziani O, Coviello R, Pirro MR, Dianzani F, Antonelli G.

Clin Diagn Lab Immunol. 2003 Jan;10(1):70-7.

Supplemental Content

Loading ...
Support Center